Retention of CD34 + CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors

Leukemia

Volumn 26, Issue 9, 2012, Pages 2142-2143

  Minami, Y ^a   Abe, A ^a,b   Minami, M ^a   Kitamura, K ^c   Hiraga, J ^d   Mizuno, S ^d   Ymamoto, K ^e   Sawa, M ^f   Inagaki, Y ^f   Miyamura, K ^g   Naoe, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c Ichinomiya Municipal Hospital   (Japan)

^d TOYOTA MEMORIAL HOSPITAL   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f ANJO KOSEI HOSPITAL   (Japan)

^g JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB;

APOPTOSIS; CANCER STEM CELL; CANCER THERAPY; CD34 SELECTION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; HEMATOPOIETIC STEM CELL; LETTER; LEUKEMIA CELL; MEGAKARYOCYTE ERYTHROID PROGENITOR; MONONUCLEAR CELL; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR REGRESSION;

AFTERCARE; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; NEOPLASTIC STEM CELLS; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES;

EID: 84865864740     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.73     Document Type: Letter

References (11)

1. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396-409.
2. Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011; 118: 5565-5572.
3. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501-1510.
4. Shami PJ, Deininger M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012; 26: 214-224.
5. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. New Engl J Med 2004; 351: 657-667. (Pubitemid 39063268)
6. Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M et al. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol 2008; 88: 471-475.
7. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010; 24: 1823-1833.
8. Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM et al. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 2011; 17: 6812-6821.
9. Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP. Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL + cells. Leukemia 2009; 23: 1205-1206.
10. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14: 485-493.
11. Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009; 114: 3459-3463.